Helios Klinikum Gifhorn, Campus 6, 38518, Gifhorn, Germany.
Klinik für Allgemein- und Viszeralchirurgie, Universitätsmedizin Oldenburg, Pius-Hospital Oldenburg, Georgstraße 12, 26121, Oldenburg, Germany.
Trials. 2023 Feb 1;24(1):76. doi: 10.1186/s13063-023-07089-3.
Incisional hernia is a frequent complication following loop ileostomy reversal. Incisional hernias are associated with morbidity, loss of health-related quality of life and costs and warrant the investigation of prophylactic measures. Prophylactic mesh implantation at the time of surgical stoma reversal has shown to be a promising and safe method to prevent incisional hernias in this setting. However, the efficacy of this method has not yet been investigated in a large multicentre randomised-controlled trial (RCT) with adequate external validity. The P.E.L.I.O.N. trial will evaluate the efficacy of prophylactic mesh reinforcement after loop ileostomy closure in decreasing the rate of incisional hernia versus standard closure alone.
P.E.L.I.O.N. is a multicentre, patient- and observer-blind RCT. Patients undergoing loop ileostomy closure will undergo intraoperative 1:1 randomisation into either abdominal wall closure with a continuous slowly absorbable suture in small-stitch technique without mesh reinforcement (control group) or abdominal wall closure with an additional reinforcement with a retromuscular non-absorbable, macro-pore (pore size ≥ 1000 μm or effective porosity >0%) light-weight monofilament or mixed structure mesh. A total of 304 patients (152 per group) will need to be randomised in the study. Based on inclusion and exclusion criteria, 1,014 patients are expected to be screened for eligibility in order to recruit the necessary number of patients. The primary endpoint will be the frequency of incision hernias within 24 months according to the European Hernia Society definition. Secondary endpoints will be the frequency of surgical site occurrences (including surgical site infections, wound seromas and hematomas, and enterocutaneous fistulas), postoperative pain, the number of revision surgeries and health-related quality of life. Safety will be assessed by measuring postoperative complications ≥ grade 3 according to the Dindo-Clavien classification.
Depending on the results of the P.E.L.I.O.N. trial, prophylactic mesh implantation could become the new standard for loop ileostomy reversal.
DRKS00027921, U1111-1273-4657.
切口疝是肠袢式回肠造口还纳术后常见的并发症。切口疝与发病率、健康相关生活质量的丧失和成本有关,因此需要研究预防措施。在手术造口还纳时预防性植入补片已被证明是一种有前途且安全的方法,可以预防这种情况下的切口疝。然而,这种方法的有效性尚未在具有足够外部有效性的大型多中心随机对照试验(RCT)中进行研究。PELION 试验将评估在回肠造口关闭后预防性使用补片加固腹壁以降低切口疝发生率与单纯标准关闭相比的效果。
PELION 是一项多中心、患者和观察者双盲 RCT。接受肠袢式回肠造口还纳术的患者将在术中进行 1:1 随机分组,一组接受连续小缝线的腹壁关闭,不使用补片加固(对照组),另一组接受腹直肌后非吸收性、大孔(孔径≥1000μm 或有效孔隙率>0%)轻质单丝或混合结构补片的额外加固。研究需要随机分组 304 例患者(每组 152 例)。根据纳入和排除标准,预计将对 1014 例患者进行筛选,以招募所需数量的患者。主要终点是根据欧洲疝学会的定义,24 个月内切口疝的发生率。次要终点是手术部位并发症的发生率(包括手术部位感染、伤口血清肿和血肿、肠皮肤瘘)、术后疼痛、再手术次数和健康相关生活质量。安全性将通过测量术后并发症≥根据 Dindo-Clavien 分类的 3 级来评估。
根据 PELION 试验的结果,预防性补片植入可能成为肠袢式回肠造口还纳术的新标准。
DRKS00027921,U1111-1273-4657。